BioCardia Inc (BCDA)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
Nov 04, 13:10
BioCardia Enterprise Value: 3.655M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 3.655M |
| October 31, 2024 | 3.528M |
| October 30, 2024 | 3.613M |
| October 29, 2024 | 3.719M |
| October 28, 2024 | 4.165M |
| October 25, 2024 | 3.719M |
| October 24, 2024 | 3.676M |
| October 23, 2024 | 3.846M |
| October 22, 2024 | 4.101M |
| October 21, 2024 | 4.271M |
| October 18, 2024 | 4.292M |
| October 17, 2024 | 4.207M |
| October 16, 2024 | 4.176M |
| October 15, 2024 | 3.761M |
| October 14, 2024 | 4.080M |
| October 11, 2024 | 4.207M |
| October 10, 2024 | 4.314M |
| October 09, 2024 | 4.271M |
| October 08, 2024 | 4.207M |
| October 07, 2024 | 4.292M |
| October 04, 2024 | 4.398M |
| October 03, 2024 | 4.547M |
| October 02, 2024 | 4.441M |
| October 01, 2024 | 4.908M |
| September 30, 2024 | 5.206M |
| Date | Value |
|---|---|
| September 27, 2024 | 4.823M |
| September 26, 2024 | 4.441M |
| September 25, 2024 | 4.037M |
| September 24, 2024 | 3.698M |
| September 23, 2024 | 3.825M |
| September 20, 2024 | 3.974M |
| September 19, 2024 | 4.908M |
| September 18, 2024 | 5.121M |
| September 17, 2024 | 4.505M |
| September 16, 2024 | 4.568M |
| September 13, 2024 | 4.887M |
| September 12, 2024 | 4.590M |
| September 11, 2024 | 4.356M |
| September 10, 2024 | 4.037M |
| September 09, 2024 | 3.698M |
| September 06, 2024 | 3.400M |
| September 05, 2024 | 3.889M |
| September 04, 2024 | 4.059M |
| September 03, 2024 | 4.675M |
| August 30, 2024 | 5.057M |
| August 29, 2024 | 7.117M |
| August 28, 2024 | 3.252M |
| August 27, 2024 | 3.804M |
| August 26, 2024 | 4.462M |
| August 23, 2024 | 3.868M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.252M
Minimum
Aug 28 2024
76.39M
Maximum
Dec 15 2020
23.81M
Average
21.72M
Median
Feb 24 2022
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 33.57B |
| Theriva Biologics Inc | -12.69M |
| Zevra Therapeutics Inc | 451.06M |
| PetIQ Inc | -- |
| Instil Bio Inc | 120.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.646M |
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 1.652M |
| EPS Diluted (Quarterly) | -0.88 |
| Profit Margin (Quarterly) | -54.87K% |
| Earnings Yield | -224.2% |
| Normalized Earnings Yield | -224.17 |